bioAffinity Technologies, Inc.BIAFEarnings & Financial Report
bioAffinity Technologies, Inc. is a clinical-stage biotechnology firm focused on developing non-invasive in vitro diagnostic tests for early detection of cancer and respiratory diseases. It serves global healthcare markets, with a core mission to deliver accessible, high-accuracy diagnostic solutions that improve patient outcomes and reduce overall healthcare system costs.
Revenue
$2.2M
Gross Profit
N/A
Operating Profit
$-2.9M
Net Profit
$-3.0M
Gross Margin
N/A
Operating Margin
-133.5%
Net Margin
-134.4%
YoY Growth
-0.3%
EPS
$-17.27
bioAffinity Technologies, Inc. Q4 FY2024 Financial Summary
bioAffinity Technologies, Inc. reported revenue of $2.2M (down 0.3% YoY) for Q4 FY2024, with a net profit of $-3.0M (down 25.0% YoY) (-134.4% margin).
Key Financial Metrics
| Total Revenue | $2.2M |
|---|---|
| Net Profit | $-3.0M |
| Gross Margin | N/A |
| Operating Margin | -133.5% |
| Report Period | Q4 FY2024 |
bioAffinity Technologies, Inc. Annual Revenue by Year
bioAffinity Technologies, Inc. annual revenue history includes year-by-year totals (for example, 2025 revenue was $6.2M).
| Year | Annual Revenue |
|---|---|
| 2025 | $6.2M |
| 2024 | $9.4M |
bioAffinity Technologies, Inc. Quarterly Revenue & Net Profit History
bioAffinity Technologies, Inc. results over the last 8 reported quarters, including revenue, net profit and year-over-year growth.
| Quarter | Revenue | Revenue YoY | Net Profit | Net Margin |
|---|---|---|---|---|
| Q4 FY2025 | $1.6M | -27.8% | $-3.1M | -197.0% |
| Q3 FY2025 | $1.4M | -38.5% | $-5.1M | -349.3% |
| Q2 FY2025 | $1.3M | -47.1% | $-4.1M | -319.9% |
| Q1 FY2025 | $1.9M | -23.0% | $-2.7M | -143.5% |
| Q4 FY2024 | $2.2M | -0.3% | $-3.0M | -134.4% |
| Q3 FY2024 | $2.4M | +687.4% | $-2.0M | -85.1% |
| Q2 FY2024 | $2.4M | +12047.4% | $-2.1M | -88.0% |
| Q1 FY2024 | $2.4M | +261180.2% | $-2.0M | -81.5% |
Income Statement
| Q1 2024 | Q2 2024 | Q3 2024 | Q4 2024 | Q1 2025 | Q2 2025 | Q3 2025 | Q4 2025 | |
|---|---|---|---|---|---|---|---|---|
| Revenue | $2.4M | $2.4M | $2.4M | $2.2M | $1.9M | $1.3M | $1.4M | $1.6M |
| YoY Growth | 261180.2% | 12047.4% | 687.4% | -0.3% | -23.0% | -47.1% | -38.5% | -27.8% |
Balance Sheet
| Q1 2024 | Q2 2024 | Q3 2024 | Q4 2024 | Q1 2025 | Q2 2025 | Q3 2025 | Q4 2025 | |
|---|---|---|---|---|---|---|---|---|
| Assets | $8.0M | $6.7M | $6.6M | $6.5M | $5.5M | $4.8M | $11.5M | $11.0M |
| Liabilities | $2.8M | $3.2M | $3.4M | $3.9M | $4.1M | $6.9M | $2.6M | $3.7M |
| Equity | $5.3M | $3.4M | $3.1M | $2.6M | $1.4M | $-2.1M | $8.9M | $7.3M |
Cash Flow
| Q1 2024 | Q2 2024 | Q3 2024 | Q4 2024 | Q1 2025 | Q2 2025 | Q3 2025 | Q4 2025 | |
|---|---|---|---|---|---|---|---|---|
| Operating CF | $-2.3M | $-1.5M | $-1.7M | $-1.7M | $-1.6M | $-2.6M | $-2.5M | $-2.6M |